聚ADP核糖聚合酶抑制剂用于卵巢癌治疗的研究进展

摘要

Ovarian cancer is the leading cause of death in women suffering from cancer,with a high mortality rate in gyneco?logical cancer. Poly(ADP-ribose)polymerase(PARP)inhibitors cause targeted tumor cell death in homologous recombination(HR)-deficient cancers,including breast cancer susceptibility gene(BRCA)tumors,and the mechanism is called"synthetic lethality". At present,there are three PARP inhibitors approved by FDA for the treatment of advanced ovarian cancer with BRCA-mutation. This pa?per reviews the role of PARP inhibitors in the treatment of ovarian cancer in clinical trial,elaborates the therapeutic mechanism of PARP inhibitors,and lights the way for the development of anti-ovarian cancer drugs.%卵巢癌是导致女性死亡的主要癌症之一,死亡率在妇科癌症中居高不下.聚ADP核糖聚合酶(PARP)抑制剂可靶向杀灭同源重组修复缺陷的肿瘤细胞,包括乳腺癌易感基因(BRCA)突变的癌细胞,这种机制被称为协同致死效应.目前已有3个PARP抑制剂被FDA批准用于治疗晚期BRCA突变的卵巢癌.本文旨在阐述PARP抑制剂治疗卵巢癌的作用机制,并对已进入临床试验阶段的PARP抑制剂进行综述,以期为开发新的卵巢癌治疗药物提供参考.